Cancer Gene Therapy Market Size Hit US$ 4,082.5 million by 2026

The global cancer gene therapy market was valued at $385.8 million and is expected to reach $4,082.5 million by 2026, registering a CAGR of 35.9% through 2026.

High prevalence of incidence of cancer, surge in geriatric population, and increase in funding from governmental and non-governmental organizations for R&D drive the growth of the global cancer gene therapy market. However, high cost for gene therapy and adverse effects such as immune response hamper the market growth. On the contrary, increase in the adoption rate due to technological advancements and high growth potential in the untapped markets in the developing countries such as India and China would create lucrative opportunities in the coming years.

Rising government initiatives in emerging economies for promoting developments in gene therapies will positively impact the cancer regenerative medicine market's growth. The government often implements several laws and initiatives to motivate scientists and researchers to perform extensive analyses of gene therapies. Furthermore, the government also funds various studies that are carried out for developing molecular therapies utilized in the treatment of cancer. The aforementioned factors should escalate the industry's growth.

Request to Get Free Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/29083

There have been several advancements in the biotechnology sector that have proven beneficial for the industry's growth. Several viral vectors have been introduced in the market that work efficiently for carrying out gene transfers. Researchers vigorously work on studying the efficacy and efficiency of the viral, as well as non-viral, vectors that are utilized in gene therapy. Newly developed viral vectors are capable of inhibiting the growth of tumor-inducing genes and are preferred by biopharmaceutical companies. Moreover, healthcare professionals working on gene therapy have started trusting and preferring these viral vectors for treating cancer patients. Therefore, growing advancements will ensure the availability of superior quality vectors for gene transfer, which will foster the market's growth.

The gene transfer segment is likely to see the fastest CAGR of 36.7% during the forecast period. This is due to the increase in funding for the development of gene transfer therapy to effectively treat cancer. Nonetheless, oncolytic virotherapy therapy segment was the largest in 2017, capturing over 43% share of the market share.

In 2017, the market in North America was the largest, grabbing more than half of the total market share owing to increase in the number of viral infection cases and high prevalence of cancer and other inherited disorders in the region. However, the Asia-Pacific market is likely to show the fastest CAGR of 39.4% through 2026. This is due to several government initiatives to improve the healthcare infrastructure in developing economies. The other regions analyzed in the report include Europe and Latin America, Middle East and Africa (LAMEA).

The types in the cancer gene market are categorized into in-vivo and ex-vivo. The in-vivo segment of the cancer gene therapy market was valued over USD $350 million in 2018 and will experience substantial growth throughout the analysis period. In-vivo gene therapy is a cost-effective option since it avoids the tedious process of removing cells from a patient's body. Furthermore, in-vivo cancer gene therapy is widely expected to treat cystic fibrosis, which positively influences business growth. However, in recent times, several high-profile, adverse events pertaining to gene therapies were recorded that has reduced its demand, thereby lowering the pace of segmental growth.

Based on product, the global market is bifurcated into viral vectors and non-viral vectors. The viral vectors segment of cancer gene therapy is anticipated to foresee around 23% growth throughout the analysis timeframe. Adenovirus is one of the highly preferred viral vectors that has commendable transductional efficiency that raises its adoption. Moreover, the adenovirus vector reduces the risk of mutagenesis. Besides, other viral vectors are also efficient and enable long-term DNA expression, reducing the mortality rate in patients suffering from cancer. The aforementioned factors will spur the viral vectors' segment growth.

Request to Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/29083

The report analyzes and forecasts the cancer gene therapy market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global cancer gene therapy market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the cancer gene therapy market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of cancer gene therapy market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The main objective of this report is to aid the user in understanding the market as a whole, its definitions, segmentation, market potential, influential trends, and the barriers that it is facing. Meticulous research and analysis were an important part of the report preparation. Those reading the report will be able to get a detailed understanding about the market. Industry experts have verified and checked the data and information that have been taken from credible sources like websites, annual reports of companies, journals, and other resources. In order give the facts and data a pictorial form, diagrams, graphs, pie charts, and other representations have been used. That augments the visual appeal of the report and makes understanding it much easier.

Key Players:

The key players operating in the global cancer gene therapy market include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

Other prominent players in the value chain include Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBiono GeneTech, and Altor Bioscience.

Key financial developments of a particular company and product & company overview are some of the elements that help in acquiring information about top vendors in the market. This particular section has also included a SWOT analysis of the companies featured in the report. This will help the audience in knowing about opportunities, strengths, threats and weaknesses that are facing by the key vendors in the chemical and material industry across the world. As the competitive landscape is the most valuable part of any report, it consists of all the required information for the detailed study of top players functioning in the industries. It is also an interesting part to find how exactly these key manufacturers implement various strategies to secure the top rank in the industry. Such an in-depth information is useful for the new entrants into the industry as they would be able to learn a bit from these key vendors. Similarly, the information provided in the research report will also be valuable for the renowned key players as well, as they come to know the strategies of their counterparts to sustain in the competitive industry.

View Full Report@ https://www.visionresearchreports.com/global-cancer-gene-therapy-market-size-share-growth-trends-company-analysis-and-forecast-2019-2026/29083

Report Segmentation:

By Therapy

• Gene Induced Immunotherapy
  • Delivery of Cytokines Gene
  • Delivery of Tumor Antigen Gene
• Oncolytic Virotherapy
  • Adenovirus
  • Lentivirus
  • Retro Virus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Alpha Virus
  • Vaccinia Virus
  • Simian Virus
  • Others
• Gene Transfer
  • Naked/Plasmid Vectors
  • Electroporation
  • Sonoportion
  • Magnetofection
  • Gene Gun

By End User

• Hospitals
• Diagnostics Centers
• Research Institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Republic of South Africa
  • Saudi Arabia
  • Rest of LAMEA

Report coverage

• Analysis Period: 2015 – 2026
• Base Year: 2018
• Forecast Data: 2019 – 2026
• Regional Scope: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
• Report Coverage: Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

• To analyze and study the global cancer gene therapy capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026)
• Focuses on the key cancer gene therapy manufacturers, to study the capacity, production, value, market share and development plans in future
• Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
• To define, describe and forecast the market by type, application and region
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks
• To identify significant trends and factors driving or inhibiting the market growth
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies

Request to Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/29083

Table of Content

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. REGULATION AND REIMBURSEMENT SCENARIO
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 CANCER GENE THERAPY MARKET, BY THERAPY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLYTIC VIROTHERAPY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Adenovirus
4.2.5. Lentivirus
4.2.6. Retro virus
4.2.7. Adeno associated virus
4.2.8. Herpes simplex virus
4.2.9. Alpha Virus
4.2.10. Vaccinia Virus
4.2.11. Simian Virus
4.2.12. Others

4.3. GENE TRANSFER

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Naked plasmid vector
4.3.5. Electroporation
4.3.6. Sonoportion
4.3.7. Magnetofection
4.3.8. Gene Gun

4.4. GENE-INDUCED IMMUNOTHERAPY

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Delivery of cytokines gene
4.4.5. Delivery of tumor antigen gene

CHAPTER 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Cancer gene therapy Market by Therapy

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Cancer gene therapy Market by Therapy

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. Australia market size and forecast
5.4.3.4. India market size and forecast
5.4.3.5. South Korea market size and forecast
5.4.3.6. Taiwan market size and forecast
5.4.3.7. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Brazil market size and forecast
5.5.3.2. Turkey market size and forecast
5.5.3.3. Saudi Arabia market size and forecast
5.5.3.4. South Africa market size and forecast
5.5.3.5. Rest of LAMEA market size and forecast

5.5.4. LAMEA Cancer gene therapy Market by Therapy

CHAPTER 6 COMPANY PROFILES

6.1. ADAPTIMMUNE

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. GLAXOSMITHKLINE

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. BLUEBIRD BIO, INC.

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. MERCK

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. CELGENE

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. SHANGHAI SUNWAY BIOTECH

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. BIOCANCELL

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. SHENZHEN SIBIONO GENETECH

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. SYNERGENE THERAPEUTICS

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. ONCOGENEX PHARMACEUTICALS

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments

Request to Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/29083​